| View |
|
BR-1263
|
Diphtheria, Tetanus, Pertussis, Hepatitis B Recombinant and Haemophilus influenza B Tyoe (Hib) Vaccine
|
Eupenta
|
|
Solution for IM Injection
|
Prescription Drug (RX)
|
0.5 mL colorless glass vial, with grey chlorobutyl rubber stopper and aluminum flip-off with propylene flip-off cap x 1's (box of 10's); single dose
|
Vaccine
|
LG Chem Limited
|
Korea
|
|
Glovax Biotech Corp
|
|
Renewal
|
03 January 2023
|
13 March 2028
|
| View |
|
BR-1264
|
Diphtheria, Tetanus, Pertussis, Hepatitis B Recombinant and Haemophilus influenza B Tyoe (Hib) Vaccine
|
Eupenta
|
|
Solution for IM Injection
|
Prescription Drug (RX)
|
5mL USP Type I Vial with grey chlorobutyl rubber stopper and aluminum flip-off seal cap x 1's (box of 10's); Multidose
|
Vaccine
|
LG Chem Limited
|
Korea
|
|
Glovax Biotech Corp
|
|
Renewal
|
04 January 2023
|
13 March 2028
|
| View |
BR-1265_PI_01.pdf
|
BR-1265
|
Adalimumab
|
Humira
|
40mg/ 0.4mL
|
Solution for Injection, Pre-Filled Pen (Mai)
|
Prescription Drug (Rx)
|
In a box of 2 blister trays each having a single-use modified auto-injector pen containing 1 mL type I pre-filled syringe x 0.4 mL with plunger stopper, a fixed 29G 1/2 needle witn needle shield (thermoplastic elastomer) and an alcohol swab
|
Antirheumatic
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
|
Abbott Laboratories
|
|
Monitored Release
|
24 September 2019
|
22 March 2025
|
| View |
BR-1266_PI_01.pdf
|
BR-1266
|
Evolocumab
|
Repatha
|
140 mg/mL
|
Solution for Injection in Pre-filled Autoinjector
|
Prescription Drug (Rx)
|
Prefilled autoinjector/pen (AI/Pen)
with a Type 1 glass prefilled
syringe (PFS)
|
Anti-PCSK9 Monoclonal Antibody
|
Amgen Manufacturing Ltd.
|
U.S.A.
|
|
|
ZUELLIG PHARMA CORPORATION
|
Monitored Release
|
23 April 2018
|
23 April 2025
|
| View |
BR-1267_PI_01.pdf
|
BR-1267
|
Evolocumab
|
Repatha
|
140 mg/mL
|
Pre-filled Syringe for Injection
|
Prescription Drug (Rx)
|
1 mL Type I glass syringe
|
Anti-PCSK9 Monoclonal Antibody
|
Amgen Manufacturing Ltd.
|
U.S.A.
|
|
|
ZUELLIG PHARMA CORPORATION
|
Monitored Release
|
23 April 2018
|
23 April 2025
|
| View |
|
BR-1268
|
Insulin aspart
|
Fiasp Flextouch
|
100 Units/mL
|
Solution for Injection (SC/IV)
|
Prescription (Rx) Drug
|
3 I 3 mL-net content Type I glass cartridge with halobutyl plunger, and halobutyl/polyisoprene stopper contained in
pre-filled
multidose disposable pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene (Box of 5's)
|
-
|
Novo Nordisk A/S
|
Denmark
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Renewal
|
19 October 2023
|
09 May 2028
|
| View |
|
BR-1269
|
Insulin aspart
|
Fiasp
|
100 Units/mL
|
Solution for Injection (IV/SC)
|
Prescription (Rx) Drug
|
10 mL-net content Type I glass
halobutyl/polyisoprene rubber disc and protective plastic.
cap (Box of 1's)
|
Insulins and Analogues
|
Novo Nordisk A/S
|
Denmark
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Renewal
|
07 November 2023
|
09 May 2028
|
| View |
BR-1270_PI_01.pdf
|
BR-1270
|
Insulin Glargine/ Lixisenatide
|
Soliqua
|
3.64 mg (equivalent to 100 Units of Insulin glargine) / 50 mcg per mL
|
Solution for Injection (SC)
|
Prescription (Rx) Drug
|
3 mL-net content Type I glass cartridge with black bromobutyl rubber plunger stopper, aluminum flanged cap with punched laminated sealing disk assembled into a disposable pen-injector made of polypropylene (Box of 1's, 3's and 5's).
|
Long-acting Insulin and Analogue.
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
|
Sanofi-Aventis Philippines, Inc.
|
Sanofi-Aventis Philippines, Inc.
|
Initial (from Monitored Release)
|
06 March 2024
|
09 May 2028
|
| View |
BR-1271_PI_01.pdf
|
BR-1271
|
Insulin Glargine/ Lixisenatide
|
Soliqua
|
3.64 mg (equivalent to 100 Units of Insulin glargine) / 33 mcg per mL
|
Solution for Injection (SC)
|
Prescription (Rx) Drug
|
3 mL-net content Type I glass cartridge with black bromobutyl rubber plunger stopper, aluminum flanged cap with punched laminated sealing disk assembled into a disposable pen-injector made of polypropylene (Box of 1's, 3's and 5's).
|
Long-acting Insulin and Analogue
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
|
Sanofi-Aventis Philippines, Inc.
|
Sanofi-Aventis Philippines, Inc.
|
Initial (from Monitored Release)
|
06 March 2024
|
09 May 2028
|
| View |
|
BR-1275
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1275
|
31 December 2022
|
07 June 2028
|
| View |
|
BR-1276
|
Human Albumin
|
Alburx
|
250 g/L (25 % w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Automatic Renewal
|
05 January 2023
|
07 June 2028
|
| View |
|
BR-1277
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1277
|
03 January 2023
|
07 June 2028
|
| View |
|
BR-1278
|
Human Albumin
|
Alburx
|
250 g/L (25% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1278
|
31 December 2022
|
07 June 2028
|
| View |
|
BR-1280
|
Atezolizumab
|
Tecentriq
|
60 mg/mL (1.2 g/20 mL)
|
Concentrate for Solution for
Infusion
|
Prescription Drug (RX)
|
Type I glass vial with rubber stopper and aluminum
seal with flip-off cap x 20 mL (Box of 1's)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
N/A
|
Roche (Philippines) Inc.
|
N/A
|
Monitored Release (Variation)
|
22 February 2023
|
22 February 2028
|
| View |
|
BR-1281
|
Quadrivalent Seasonal Influenza Vaccine (Surface
Antigen, Inactivated) 2024 Southern Hemisphere Strain
|
Influvac Tetra
|
(See reverse for the formulation)
|
Suspension for Injection (IM/SC)
|
Prescription Drug (RX)
|
0.5 mL in 1 mL Type I pre-filled glass syringe with grey bromobutyl rubber plunger with needle (Box of 1's).
|
Vaccine
|
Abbott Biologicals B.V.
|
Netherlands
|
|
Abbott Laboratories
|
Abbott Laboratories
|
Monitored Release (Strain Clearance)
|
20 February 2024
|
20 February 2025
|
| View |
|
BR-1282
|
Eptacog alfa activated
|
NovoSeven RT
|
1 mg/vial (50KIU/vial)
|
Powder And Solvent For Solution For Injection
|
Prescription Drug (RX)
|
Vial: Type I glass vial closed with chlorobutyl rubber stopper, covered with an aluminium cap. The closed vial is equipped with a polypropylene tamper-evident snap-off cap. Pre-filled syringe: Type I glass barrel with a polypropylene backstop and bromobutyl rubber plunger. The syringe cap consists of bromobutyl rubber and polypropylene tamper evident seal. Plunger rod: made of polypropylene.
|
Blood Coagulation Factor
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines) Inc.
|
|
Renewal
|
01 August 2023
|
25 July 2028
|
| View |
|
BR-1284
|
Isophane Insulin (Recombinant DNA)
|
Humulin N
|
100 Units/mL
|
Suspension for Injection (SC)
|
Prescription Drug (RX)
|
Type I siliconized glass cartridge sealed with rubber closures consisting of a chlorobutyl plunger and an aluminum disc seal x 3 mL (Box of 5's)
|
-
|
Lilly France S.A.S.
|
France
|
N/A
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Renewal
|
11 October 2022
|
31 October 2027
|
| View |
|
BR-1289
|
Rotavirus Vaccine (Live, Attenuated)
|
Rotasiil
|
Formulation: After reconstitution, each dose (2.5 mL) contains:
Live Attenuated Bovine-Human Rotavirus Reassortant [G1, G2, G3, G4 and G9]* >10^5.6 FFU/Serotype *Grown on vero cells
|
Freeze-dried Powder for Oral Suspension
|
Prescription Drug (RX)
|
Type I clear tubular glass vial + Type I glass vial x 2.5 mL (Citrate Bicarbonate buffer solution as diluent) (Box of 1's)
|
-
|
Serum Institute of India Private Limited
|
India
|
N/A
|
Faberco Life Sciences Inc.
|
N/A
|
-
|
18 March 2022
|
08 February 2027
|
| View |
|
BR-1290
|
Inactivated Poliomyelitis Vaccine (Types 1, 2 And 3)
|
Poliovac
|
0.5 mL
|
Suspension For Injection (IM/SC)
|
Prescription Drug (RX)
|
Type I Clear Vial x 0.5 mL (Box of 1's, 10's and 50's)
|
-
|
Serum Institute of India Private Limited
|
India
|
N/A
|
Faberco Life Sciences Inc.
|
Faberco Life Sciences Inc.
|
Initial (Variation)
|
09 February 2023
|
09 February 2028
|
| View |
BR-1291_PI_01.pdf
|
BR-1291
|
Liraglutide
|
SAXENDA
|
6mg/ mL
|
Solution for Injection
|
Prescription Drug (Rx)
|
Cartridge (type 1 glass) with a plunger (bromobutyl) and a stopper (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polyacetal, polycarbonate and acrylonitrile butadiene styrene.
|
Anti-Obesity
|
NOVO NORDISK A/S
|
Denmark
|
|
NOVO NORDISK PHARMACEUTICALS (PHILS.) INC.
|
NOVO NORDISK PHARMACEUTICALS (PHILS.) INC.
|
Monitored Release
|
25 April 2019
|
25 April 2025
|